Healthcare/Biotech Analysts, along with KOL Dr. Kwiatkowski of Harvard Medical School, discuss Amgen’s PRMT5 Inhibitor on an Analyst/Industry conference call to be held on October 17 at 2:30 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M
- Stifel disagrees with negative reaction in Ideaya shares after Amgen data
- Ideaya has positive read from Amgen PRMT5 data, says Oppenheimer
- Amgen’s PRMT5 drug shows 5 partial responses from 31 patients, STATnews reports
- Jefferies ‘optimistic’ about Amgen PRMT5 data following embargo